GeminiBio Launches aiMOS, AI-Enabled Media Optimization Service for Cell Therapy Manufacturing

New service leverages AI/ML and multi-omics data to design custom media supplements that improve cell therapy performance and manufacturing outcomes.

Published on Feb. 10, 2026

Got story updates? Submit your updates here. ›

GeminiBio, a biopharma and advanced therapy raw materials supplier, has announced the launch of aiMOS™, a first-of-its-kind service that uses artificial intelligence/machine learning (AI/ML) and multi-omics data to design custom media supplements to improve the performance, consistency, and scalability of cell therapy manufacturing. Developed in collaboration with Tolemy Bio, aiMOS is designed to help cell therapy innovators enhance critical quality attributes (CQAs), increase manufacturing efficiency, and reduce overall cost across T-cell, NK-cell, TCR, and TIL development and manufacturing processes.

Why it matters

Cell therapy developers often struggle with one-size-fits-all media that doesn't align with their unique processes, cell sources, and activation strategies. aiMOS aims to address this challenge by providing a data-driven, process-specific media optimization service that can enhance cell therapy performance and manufacturing outcomes.

The details

aiMOS reads the metabolic and behavioral fingerprints of cells in culture, identifies the key levers that drive cell therapy performance, potency and yield, and then predicts the ideal supplement composition and concentrations to specifically enhance cell performance. This can help cell therapy developers drive superior performance, lower cost per dose, shorten development timelines, and scale with confidence from research to late-stage clinical and commercial manufacturing.

  • aiMOS is available immediately to cell therapy developers worldwide.

The players

GeminiBio

A biopharma and advanced therapy raw materials supplier and a portfolio company of BelHealth Investment Partners, LLC. GeminiBio provides serum, customized media, buffers, and process liquids to biopharma and advanced therapy companies.

Tolemy Bio

A Cambridge, UK-based TechBio company building Orbit, an AI-native control panel for the cell that helps teams design, optimize, and control cell culture processes for advanced therapeutic development and production.

Brian Parker

Chief Executive Officer at GeminiBio.

Alex Ward, PhD

Co-founder of Tolemy Bio.

Robert Perry

Chief Scientific Officer at GeminiBio.

Got photos? Submit your photos here. ›

What they’re saying

“Cell therapy developers shouldn't have to accept one‑size‑fits‑all media when their processes, cell sources, and activation strategies are so different.”

— Brian Parker, Chief Executive Officer (GeminiBio)

“By applying causal AI modelling to a cell's metabolic and behavioral fingerprints, our platform can identify the exact levers that drive cell therapy performance, potency and yield. With that information, we can then predict the ideal supplement composition and concentrations to specifically enhance cell performance.”

— Alex Ward, PhD, Co-founder (Tolemy Bio)

“As cell therapies advance, customers need partners who provide both high‑quality raw materials and pathways to process optimization. aiMOS builds on our industry‑leading position in human AB serum and expands our ability to help developers improve CQAs and reduce manufacturing risk, backed by the documentation and support required for clinical and commercial success.”

— Robert Perry, Chief Scientific Officer (GeminiBio)

What’s next

aiMOS is available immediately to cell therapy developers worldwide.

The takeaway

aiMOS provides cell therapy developers with a practical, high-impact way to achieve better performance and manufacturing outcomes by leveraging AI/ML and multi-omics data to design custom media supplements tailored to the specific needs of each cell type.